Highest-materiality recent filing
Nuvation Bio completes full greenshoe, raising $287.5M in convertible notes
Underwriters exercised full over-allotment for additional $37.5M of 0.75% Convertible Senior Notes due 2032.
Nuvation Bio closes $250M 0.75% convertible senior notes offering due 2032
$250M aggregate principal of 0.75% Convertible Senior Notes due 2032; initial conversion price ~$7.84/share (35% premium).
Nuvation Bio stockholders elect directors, ratify KPMG, approve say-on-pay at 2026 annual meeting
Class A directors Robert B. Bazemore Jr. and Robert Mashal elected with 197.7M and 216.8M votes for, respectively.
Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago
Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.
Nuvation Bio Reports Q4 2025 Revenue of $15.7M, 216 New IBTROZI Patient Starts
IBTROZI (taletrectinib) launched in June 2025; 432 new patient starts by end of Q4 2025, with 216 in Q4 alone.
Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M
Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.
Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline
Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.
Nuvation Bio reports Phase 2 ORR 44.4% for safusidenib in IDH1-mutant gliomas
Safusidenib met primary endpoint with 44.4% objective response rate in 27 Japanese patients with grade 2 IDH1-mutant gliomas.
Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M
Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.
Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks
FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.
Nuvation Bio announces FDA approval of IBTROZI (taletrectinib) for ROS1+ NSCLC
FDA approved IBTROZI for adult patients with locally advanced or metastatic ROS1+ NSCLC.
Nuvation Bio stockholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting
All three proposals passed at May 21, 2025 annual meeting; quorum of 82.8% of Class A shares present.
Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025
Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.
Nuvation Bio enters commercial supply agreement with Asymchem for taletrectinib drug product
Asymchem will be non-exclusive supplier of taletrectinib drug product; Nuvation retains right to use alternate manufacturers.
Nuvation Bio: taletrectinib NDA Priority Review, $250M financing, Q4 net loss $49.4M
FDA accepted NDA for taletrectinib with Priority Review; PDUFA goal date June 23, 2025 for advanced ROS1+ NSCLC.
Nuvation Bio enters 5-year supply agreement with Asymchem for taletrectinib drug substance
Asymchem will be a non-exclusive supplier; Nuvation retains right to use alternate manufacturers.
Nuvation Bio secures up to $250M in debt and royalty financing for taletrectinib
$100M loan with Sagard; initial $50M tranche upon FDA approval of taletrectinib by Sep 30, 2025; second $50M upon first US commercial sale by Jun 30, 2026
Dr. Jerry Wang exits AnHeart Therapeutics CEO role after taletrectinib milestones achieved
Dr. Wang departed as CEO of AnHeart Therapeutics, a Nuvation Bio subsidiary, on Feb. 12, 2025.
Nuvation Bio reports Q3 net loss of $41.2M, submits NDA for taletrectinib in ROS1+ NSCLC
Net loss of $41.2M ($0.15 per share) vs $19.6M ($0.09) in Q3 2023; cash of $549.1M at Sept 30.
Nuvation Bio appoints Philippe Sauvage as CFO effective October 7, 2024
Philippe Sauvage appointed CFO; previously SVP Global Head of Operations & Access at Sanofi (2020-2024).
Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair
Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.
Nuvation Bio Q2 net loss $462.5M on $425.1M AnHeart charge; halts NUV-868 Phase 2
Net loss of $462.5M ($1.89/share) vs. $20.6M ($0.09) Q2 2023; includes $425.1M acquired IPR&D charge from AnHeart acquisition.
Nuvation Bio files 8-K/A with AnHeart financials and updated taletrectinib clinical data
Acquired AnHeart in Apr 2024; audited AnHeart FY2023 and FY2022 financials included.
Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M
Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.
Completed acquisition of AnHeart Therapeutics on April 9, 2024. Issued ~27.6M Class A shares, 851K Series A Convertible Preferred (convertible into ~85.1M shares), and ~2.9M warrants.
Nuvation Bio to acquire AnHeart Therapeutics in all-stock merger; AnHeart holders to own ~33%
Nuvation Bio to acquire AnHeart via merger; will issue ~128.7M shares of Class A common stock and ~2.9M warrants to AnHeart securityholders.
Q4 net loss $13.8M ($0.06/shr); full-year net loss $75.8M, improved from $104.2M in 2022.
Nuvation Bio appoints Robert Mashal, M.D. to board as Class II director
Dr. Mashal appointed to fill vacant board seat effective Jan. 8, 2024; term expires at 2026 annual meeting.
Nuvation Bio director Oleg Nodelman resigns from board effective December 11, 2023
Oleg Nodelman resigned as a member of the Board on December 11, 2023; resignation effective immediately.
Nuvation Bio appoints Moses Makunje as Principal Accounting Officer and Principal Financial Officer
Appointment effective Nov 27, 2023; Makunje previously VP Finance since Jan 2022.
Nuvation Bio CFO Jennifer Fox resigns effective Nov 27
CFO Jennifer Fox resigns to pursue a new opportunity; not due to any disagreement with the Company.
Nuvation Bio Q3 net loss $19.6M ($0.09/shr), cash $619.3M; DDC IND on track
Net loss narrowed to $19.6M from $27.2M YoY; loss per share $0.09 vs $0.12.
Nuvation Bio Q2 net loss narrows to $20.6M; cash $630.9M; NUV-868 studies enrolling
Net loss of $20.6M ($0.09/share) vs $34.9M ($0.16/share) in Q2 2022.
Nuvation Bio annual meeting: directors elected, KPMG ratified, 20% opposed exec pay
Director Robert B. Bazemore Jr. re-elected with 140.6M for, 50.1M withheld (26% of votes cast).
Nuvation Bio Q1 2023 net loss $21.7M; cash $646.6M; DDC IND on track for year-end
Net loss of $21.7M ($0.10 per share) vs $21.3M ($0.10) in Q1 2022.
Nuvation Bio reports Q4 2022 net loss $20.8M, cash $661M; advances NUV-868 and DDC
Net loss Q4 2022 $20.8M ($0.10/sh) vs $25.1M ($0.12/sh) Q4 2021; full-year net loss $104.2M.
Nuvation Bio files Delaware court petition to validate share increase amendments after Boxed ruling
Filed petition in Delaware Court of Chancery under Section 205 of DGCL to validate charter amendment increasing authorized shares of Class A from 500M to 1B and Class B from 20M to 60M.
Nuvation Bio updates slide deck with clinical development timeline and milestones
Filed under Regulation FD; presentation available on company website.
Nuvation Bio Q3 net loss $27.2M; cash $673.9M; NUV-868 Phase 1b on track
Net loss of $27.2M ($0.12/share) vs $22.0M ($0.11/share) in Q3 2021.
Nuvation Bio Q2 net loss $34.9M; restructures with 35% workforce cut
Cash, equivalents, marketable securities $703.8M as of June 30, 2022; runway through 2028.
Nuvation Bio discontinues NUV-422 program due to uveitis safety; cuts 35% of staff
Discontinued NUV-422 clinical program after FDA partial clinical hold due to unpredictable uveitis safety signal.
Nuvation Bio stockholders elect directors, ratify KPMG, approve 1-year say-on-pay frequency
Directors elected: Falberg 175.6M for, Nodelman 146.2M for (Class A); Hung 1.0M for (Class B).
Nuvation Bio Q1 net loss $21.3M; pipeline focus on NUV-422, NUV-868, DDC
Net loss $21.3M ($0.10 per share) vs $20.4M ($0.12) in Q1 2021.
Nuvation Bio Q4 net loss $25.1M, cash $765.4M; NUV-422 gets Fast Track
Net loss Q4 2021 was $25.1M ($0.12/share) vs $13.3M ($0.11) in Q4 2020.
Nuvation Bio to present at JPM 2022; no specific financial or pipeline updates disclosed
Company conducting investor meetings at 40th Annual J.P. Morgan Healthcare Conference starting Jan 10, 2022.
Nuvation Bio reports estimated cash of $765M as of Dec. 31, 2021
Estimated cash, cash equivalents, and marketable securities of $765M as of December 31, 2021.
Nuvation Bio Q3 2021 net loss $22.0M; cash $791.8M; NUV-422 enrollment ongoing
Net loss of $22.0M ($0.11 per share) vs $11.0M ($0.12) in Q3 2020.
Nuvation Bio terminates collaboration agreement with SPARCBIO LLC effective Jan 2022
On Oct 22, 2021, Nuvation notified SPARCBIO LLC of termination effective Jan 21, 2022 without penalty.
Nuvation Bio Q2 net loss $19.3M; cash $806.6M; NUV-422 trial expands
Net loss of $19.3M ($0.09/share) vs $8.6M loss ($0.10) in Q2 2020.
On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals
Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.
Effective October 7, 2024 (the “Appointment Date”), the Board of Nuvation Bio Inc. (the “Company”) appointed Philippe Sauvage as the Company’s Chief Financial Officer and Principal Financial Officer.
Dr. Junyuan (Jerry) Wang and Dr. Xiangmin (Min) Cui, Ph.D. were appointed as Class I and Class III directors, respectively, to the Company’s board of the directors (the “Board”).
Dr. Junyuan (Jerry) Wang and Dr. Xiangmin (Min) Cui, Ph.D. were appointed as Class I and Class III directors, respectively, to the Company’s board of the directors (the “Board”).
On January 8, 2024 the Board of Directors (the “ Board ”) of Nuvation Bio Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Mashal, M.D. to fill a vacant Board seat and to serve as a Class II director, with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders.
On December 11, 2023, Oleg Nodelman notified Nuvation Bio Inc. (the “Company”) of his intent to resign as a member of the Company’s Board of Directors (the “Board”), and he subsequently delivered a letter to the Board on December 12, 2023 documenting his resignation effective immediately.
Effective November 27, 2023, the Board of Nuvation Bio Inc. (the “Company”) appointed Moses Makunje as the Company’s Principal Accounting Officer and Principal Financial Officer.
On November 9, 2023, Jennifer Fox, the Chief Financial Officer of Nuvation Bio Inc. (the “Company”), notified the Company of her decision to pursue a new opportunity and resign from her position at the Company effective November 27, 2023.
Max materiality 0.95 · Median 0.60 · Most common event earnings